STOCK TITAN
  1. Home
  2. News
  3. BMY

Bristol-Myers Squibb Co. - BMY STOCK NEWS

Welcome to our dedicated page for Bristol-Myers Squibb Co. news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co. stock.

Bristol-Myers Squibb Co. (BMY) is a renowned American multinational pharmaceutical company headquartered in New York City. As one of the largest pharmaceutical companies globally, Bristol-Myers Squibb (BMS) consistently ranks on the Fortune 500 list. In fiscal 2022, the company achieved total revenue of $46.2 billion.

Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs across various therapeutic areas, including cardiovascular, cancer, and immune disorders. A significant area of focus for BMS is immuno-oncology, where it has established itself as a leader in drug development. Approximately 70% of BMS's total sales are derived from the U.S. market, reflecting its higher dependence on this region compared to its peers.

Recent achievements and collaborations highlight BMS's commitment to innovation and partnerships. On May 22, 2024, BMS joined NeoPhore Limited's oversubscribed Series B extension round. This additional investment will enable NeoPhore to explore novel biology associated with the DNA mismatch repair (MMR) pathway in cancer, and further advance its pre-clinical studies. NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients.

Another noteworthy collaboration was announced on June 5, 2024, with I-Mab, a U.S.-based global biotech company. This partnership will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody, with BMS's immune checkpoint inhibitor, nivolumab, and chemotherapy. The study, a multi-national Phase 1, will focus on advanced Claudin 18.2-positive gastric and esophageal cancers. BMS will supply nivolumab, which is designed to enhance T-cell function and improve anti-tumor responses.

Additionally, on June 5, 2024, Envisagenics, an AI-driven biotechnology company, announced a Series B fundraising round with participation from BMS. This funding will be utilized to further develop Envisagenics' pipeline of novel preclinical oncology assets using their cloud-based AI drug discovery platform, SpliceCore®. This collaboration underscores BMS's continued investment in innovative technologies and therapeutics.

Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. Through strategic partnerships, cutting-edge research, and a commitment to therapeutic advancements, BMS continues to make significant strides in the biopharmaceutical industry.

News

Opdivo (nivolumab) Plus Yervoy (ipilimumab) Reduced the Risk of Disease Progression or Death by 79% Versus Chemotherapy in Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer in CheckMate -8HW Trial

Rhea-AI Summary
Bristol Myers Squibb (BMY) announced results from the Phase 3 CheckMate -8HW trial evaluating Opdivo plus Yervoy compared to chemotherapy as a first-line treatment for patients with MSI-H/dMMR mCRC. The dual immunotherapy combination demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), with a reduction in the risk of disease progression or death by 79%. The safety profile for the combination remained consistent with previously reported data, with no new safety signals identified. The late-breaking data will be featured in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium and highlighted as part of the official Congress press program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Bristol Myers Squibb Data at ASCO GU 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers

Rhea-AI Summary
Bristol Myers Squibb (BMY) announced the presentation of data at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium, highlighting the company’s progress in making long-term survival outcomes a possibility for more patients with genitourinary cancers. The data includes the first presentation of results from the Phase 3 CheckMate -67T trial with a subcutaneous formulation of Opdivo, as well as four-year data from CheckMate -9ER and unprecedented eight-year data from CheckMate -214, confirming durable outcomes with Opdivo-based combinations for patients with advanced renal cell carcinoma. Additionally, the disclosure of clinical outcomes from a Phase 1 trial with BMS-986365 in metastatic castration-resistant prostate cancer showcases potential new options and therapeutic platforms that may transform treatment paradigms across tumor types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.04%
Tags
none
-
News

Healthpeak Properties Enters into a New $236 Million Joint Venture with Breakthrough Properties on the Callan Ridge Lab Campus in Torrey Pines

Rhea-AI Summary
Healthpeak Properties, Inc. (NYSE: PEAK) announced a new strategic joint venture with Breakthrough Properties, selling a 65% interest in its fully leased Callan Ridge lab campus in San Diego. The joint venture values Callan Ridge at $236 million, with a stabilized cash capitalization rate of 5.3% at an initial annual rental rate of approximately $67 per square foot.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
none
News

Breakthrough Properties Acquires Majority Interest in Callan Ridge, A Newly-Constructed, Fully-Leased Life Science Campus in Torrey Pines

Rhea-AI Summary
Breakthrough Properties (BMY) Acquires Majority Interest in Callan Ridge, a Class A Life Science Campus in San Diego Through a Joint Venture with Healthpeak Properties (PEAK)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
acquisition
-
News

European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors

Rhea-AI Summary
Bristol Myers Squibb (BMY) announces that the European Medicines Agency (EMA) has validated its marketing authorization application for repotrectinib, a next-generation tyrosine kinase inhibitor (TKI), as a treatment for ROS1 TKI-naïve and -pretreated adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) and TKI-naïve and -pretreated adult and pediatric patients 12 years and older with NTRK-positive locally advanced or metastatic solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
none
-
News

Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

Rhea-AI Summary
Bristol Myers Squibb (BMY) to Acquire RayzeBio (RYZB) for $4.1 Billion, Expanding Oncology Portfolio and Radiopharmaceutical Platform
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
acquisition
News

PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion

Rhea-AI Summary
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced that its Founded Entity, Karuna Therapeutics, Inc., and Bristol Myers Squibb (NYSE: BMY) have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
acquisition
-
News

Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics

Rhea-AI Summary
Bristol Myers Squibb (BMY) will acquire Karuna Therapeutics, Inc. (KRTX) for $14.0 billion, aiming to enhance their growth and diversify the portfolio in the neuroscience space. The transaction is expected to close in the first half of 2024, with KarXT, a first-in-class treatment for schizophrenia and Alzheimer's disease psychosis, as the key asset.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
acquisition
-
News

Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics

Rhea-AI Summary
Bristol Myers Squibb (BMY) to Acquire Karuna Therapeutics, Inc. (KRTX) for $14 Billion, Expanding Its Portfolio in Neuroscience
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
acquisition
News

Bristol Myers Squibb to Present at J.P. Morgan’s 42nd Annual Healthcare Conference

Rhea-AI Summary
Bristol Myers Squibb (NYSE: BMY) to Present at J.P. Morgan's 42nd Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
conferences

FAQ

What is the current stock price of Bristol-Myers Squibb Co. (BMY)?

The current stock price of Bristol-Myers Squibb Co. (BMY) is $57.76 as of December 24, 2024.

What is the market cap of Bristol-Myers Squibb Co. (BMY)?

The market cap of Bristol-Myers Squibb Co. (BMY) is approximately 117.1B.

What is Bristol-Myers Squibb's core business?

Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs for various therapeutic areas, including cardiovascular, cancer, and immune disorders.

Where is Bristol-Myers Squibb headquartered?

Bristol-Myers Squibb is headquartered in New York City, USA.

What was Bristol-Myers Squibb's revenue for fiscal 2022?

Bristol-Myers Squibb reported a total revenue of $46.2 billion for fiscal 2022.

What is a significant focus area for Bristol-Myers Squibb?

A significant focus area for Bristol-Myers Squibb is immuno-oncology, where it is a leader in drug development.

How much of Bristol-Myers Squibb's total sales come from the U.S. market?

Approximately 70% of Bristol-Myers Squibb's total sales are derived from the U.S. market.

What recent collaboration did Bristol-Myers Squibb announce with NeoPhore Limited?

On May 22, 2024, Bristol-Myers Squibb joined NeoPhore Limited's Series B extension round to explore novel biology associated with the DNA mismatch repair pathway in cancer.

What is the purpose of Bristol-Myers Squibb's collaboration with I-Mab?

The collaboration with I-Mab focuses on evaluating the combination of givastomig with BMS's nivolumab and chemotherapy for advanced Claudin 18.2-positive gastric and esophageal cancers.

What is SpliceCore®?

SpliceCore® is Envisagenics' cloud-based AI drug discovery platform that integrates machine learning algorithms to identify novel and disease-specific RNA splicing isoforms.

When did Bristol-Myers Squibb participate in Envisagenics' Series B fundraising round?

Bristol-Myers Squibb participated in Envisagenics' Series B fundraising round announced on June 5, 2024.

What is Bristol-Myers Squibb's mission?

Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.

Stock BMY logo
Bristol-Myers Squibb Co.

NYSE:BMY

BMY Rankings

#108 Ranked by Market Cap
#719 Ranked by Dividends

BMY Stock Data

117.15B
2.03B
0.12%
78.46%
1.27%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
PRINCETON